Delivery of DNA HIV-1 Vaccine to the Liver Induces High and Long-lasting Humoral Immune Responses

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2008 Feb 29

PMID 18304708

Citations 13

Authors

Milan Raska

Zina Moldoveanu

Jan Novak

Zdenek Hel

Lea Novak

Jadranka Bozja

Richard W Compans

Chinglai Yang

Jiri Mestecky

Affiliations

Soon will be listed here.

Abstract

The quality of immune responses induced by DNA vaccination depends on the site of DNA administration, the expression, and the properties of the encoded antigen. In the present study, we demonstrate that intravenous hydrodynamic HIV-1 envelope DNA injection resulted in high levels of expression of HIV-1 envelope antigen in the liver. When compared to the administration of DNA by i.n., i.d., i.m., and i.splenic routes, hydrodynamic vaccination induced, upon DNA boosting, levels of HIV-1 envelope-specific antibodies 40-fold higher than those elicited by the other routes tested. Hydrodynamic vaccination with 1 microg DNA induced higher humoral responses than 100 microg DNA given intramuscularly in the prime-boost regimen. High levels of envelope-specific IgG and IgA antibodies were induced in genital tract secretions after two doses of DNA followed by intranasal boosting with recombinant HIV-1 gp120 protein. Furthermore, two doses of 100 microg DNA generated interferon-gamma production in approximately 4.3+/-1.7% of CD8(+) splenocytes after in vitro stimulation with HIV-1 envelope peptides. These results demonstrate that DNA vaccines targeted to tissues with high proteosynthetic activity, such as the liver, results in enhanced immune responses.

Citing Articles

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1.

Walimbwa S, Maly P, Raskova Kafkova L, Raska M J Biomed Sci. 2024; 31(1):83.

PMID: 39169357 PMC: 11337606. DOI: 10.1186/s12929-024-01073-y.

Myomedin replicas of gp120 V3 loop glycan epitopes recognized by PGT121 and PGT126 antibodies as non-cognate antigens for stimulation of HIV-1 broadly neutralizing antibodies.

Daniel Liskova V, Kosztyu P, Kuchar M, cerny J, Bharadwaj S, Petrokova H Front Immunol. 2022; 13:1066361.

PMID: 36569830 PMC: 9772448. DOI: 10.3389/fimmu.2022.1066361.

Myomedin scaffold variants targeted to 10E8 HIV-1 broadly neutralizing antibody mimic gp41 epitope and elicit HIV-1 virus-neutralizing sera in mice.

Kuchar M, Kosztyu P, Daniel Liskova V, cerny J, Petrokova H, Vroblova E Virulence. 2021; 12(1):1271-1287.

PMID: 33993840 PMC: 8128222. DOI: 10.1080/21505594.2021.1920251.

Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies.

Wei Q, Hargett A, Knoppova B, Duverger A, Rawi R, Shen C iScience. 2020; 23(11):101711.

PMID: 33205023 PMC: 7649354. DOI: 10.1016/j.isci.2020.101711.

Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice.

Kosztyu P, Kuchar M, cerny J, Barkocziova L, Maly M, Petrokova H EBioMedicine. 2019; 47:247-256.

PMID: 31544770 PMC: 6796546. DOI: 10.1016/j.ebiom.2019.07.015.

References

Hanke T, McMichael A, Dorrell L . Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol. 2006; 88(Pt 1):1-12. DOI: 10.1099/vir.0.82493-0. View

Moldoveanu Z, Novak M, Huang W, Gilley R, Staas J, Schafer D . Oral immunization with influenza virus in biodegradable microspheres. J Infect Dis. 1993; 167(1):84-90. DOI: 10.1093/infdis/167.1.84. View

Barouch D, Santra S, Steenbeke T, Zheng X, Perry H, Davies M . Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol. 1998; 161(4):1875-82. View

Stankovics J, Crane A, Andrews E, Wu C, Wu G, Ledley F . Overexpression of human methylmalonyl CoA mutase in mice after in vivo gene transfer with asialoglycoprotein/polylysine/DNA complexes. Hum Gene Ther. 1994; 5(9):1095-104. DOI: 10.1089/hum.1994.5.9-1095. View

Donnelly J, Ulmer J, Shiver J, Liu M . DNA vaccines. Annu Rev Immunol. 1997; 15:617-48. DOI: 10.1146/annurev.immunol.15.1.617. View

Heath W, Carbone F . Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001; 19:47-64. DOI: 10.1146/annurev.immunol.19.1.47. View

Rogers J, Bigley N, Chiou H, Hull B . Targeted delivery of DNA encoding herpes simplex virus type-1 glycoprotein D enhances the cellular response to primary viral challenge. Arch Dermatol Res. 2001; 292(11):542-9. DOI: 10.1007/s004030000181. View

Heller L, Jaroszeski M, Coppola D, Pottinger C, Gilbert R, Heller R . Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo. Gene Ther. 2000; 7(10):826-9. DOI: 10.1038/sj.gt.3301173. View

Mestecky J, Moldoveanu Z, Elson C . Immune response versus mucosal tolerance to mucosally administered antigens. Vaccine. 2005; 23(15):1800-3. DOI: 10.1016/j.vaccine.2004.11.009. View

10.

Kothe D, Decker J, Li Y, Weng Z, Bibollet-Ruche F, Zammit K . Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology. 2006; 360(1):218-34. PMC: 1945152. DOI: 10.1016/j.virol.2006.10.017. View

11.

Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D . Diversity considerations in HIV-1 vaccine selection. Science. 2002; 296(5577):2354-60. DOI: 10.1126/science.1070441. View

12.

Zuber G, Zammut-Italiano L, Dauty E, Behr J . Targeted gene delivery to cancer cells: directed assembly of nanometric DNA particles coated with folic acid. Angew Chem Int Ed Engl. 2003; 42(23):2666-9. DOI: 10.1002/anie.200250446. View

13.

Zou S, Erbacher P, Remy J, Behr J . Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse. J Gene Med. 2000; 2(2):128-34. DOI: 10.1002/(SICI)1521-2254(200003/04)2:2<128::AID-JGM95>3.0.CO;2-W. View

14.

Baba T, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S . Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000; 6(2):200-6. DOI: 10.1038/72309. View

15.

Yang X, Farzan M, Wyatt R, Sodroski J . Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol. 2000; 74(12):5716-25. PMC: 112061. DOI: 10.1128/jvi.74.12.5716-5725.2000. View

16.

Rogers J, Hull B, Fink P, Chiou H, Bigley N . Murine response to DNA encoding herpes simplex virus type-1 glycoprotein D targeted to the liver. Vaccine. 2000; 18(15):1522-30. DOI: 10.1016/s0264-410x(99)00438-7. View

17.

Garzon M, Berraondo P, Crettaz J, Ochoa L, Vera M, Lasarte J . Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex. Vaccine. 2005; 23(11):1384-92. DOI: 10.1016/j.vaccine.2004.09.009. View

18.

Schatzlein A . Targeting of Synthetic Gene Delivery Systems. J Biomed Biotechnol. 2003; 2003(2):149-158. PMC: 323958. DOI: 10.1155/S1110724303209116. View

19.

Wei X, Decker J, Liu H, Zhang Z, Arani R, Michael Kilby J . Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002; 46(6):1896-905. PMC: 127242. DOI: 10.1128/AAC.46.6.1896-1905.2002. View

20.

Letvin N, Walker B . Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med. 2003; 9(7):861-6. DOI: 10.1038/nm0703-861. View